Autoimmune disease Archives

lupus autoimmune disease neutrophil citryll

News and Trends 4 Jul 2019

Dutch Antibodies for Autoimmune Diseases Boosted by €15M Series A

The Dutch biotech Citryll has raised €15M to develop antibodies that could fight autoimmune and inflammatory diseases more effectively than current treatments by inhibiting the innate immune system. The Series A funds will be used to launch the clinical development of Citryll’s lead antibody, which is designed to treat the autoimmune condition lupus. The money […]

July 4, 2019 - 2 minutesmins - By Jonathan Smith

Best in Biotech 8 May 2019

Top 10 Biotechs in Lausanne

The Swiss city of Lausanne is perhaps best known as a hub of international sport, but what many outsiders may not realize is that it’s also one of Switzerland’s biggest biotech hubs. Many of the biotechs in the city are connected to the University of Lausanne (UNIL), as well as the renowned Swiss Federal Institute […]

May 8, 2019 - 7 minutesmins - By David Cox

Interview 25 Apr 2019

European Biotechnology in 2019 and Beyond: What’s Hot and What’s Not?

We spend a lot of time focusing on specific developments in biotechnology, but sometimes it’s good to take a step back and look at the bigger picture. With this in mind, I asked three experts at our recent Refresh event in Vienna to share what is hot in European biotech right now and what trends […]

April 25, 2019 - 11 minutesmins - By Helen Albert

Galapagos Gilead filgotinib rheumatoid arthritis

News and Trends 29 Mar 2019

Galapagos Nears First Drug Approval with Phase III Success in Rheumatoid Arthritis

Galapagos has released positive data from two phase III trials testing its flagship drug candidate, filgotinib, that will let the company and its partner Gilead apply for marketing approval. 20 years after its foundation, Galapagos is finally approaching the finish line. Yesterday, the company has shared positive data from two clinical trials that together enrolled […]

March 29, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

autoimmune disorder eosinophilic esophagitis allergy milk calypso biotech

News and Trends 20 Feb 2019

Inflammatory Disease Treatment Backed by €20M Series A

The Swiss company Calypso Biotech has raised a sizeable €20M to fund its immunotherapy for an allergy-related inflammatory disease. The Series A round will help to develop Calypso’s antibody treatment for eosinophilic esophagitis, a condition where patients have an inflamed esophagus and difficulty swallowing. This condition is often linked with allergies to food, such as […]

February 20, 2019 - 2 minutesmins - By Jonathan Smith

Altheia Science gene therapy autoimmune disease

News and Trends 19 Dec 2018

Italian Biotech Raises Big Series A for ‘Gene Therapy 2.0’

Altheia Science, based in Milan, has raised €17M to fund the development of gene therapies for autoimmune diseases with the remarkable potential to be curative. “The success of our fundraising campaign is unprecedented over a Series A in Italy,” said Paolo Rizzardi, co-founder and CEO of Altheia. The funds will go towards taking the company’s […]

December 19, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

autoimmune liver disease Genkyotex organ

News and Trends 7 Nov 2018

Solid Phase II Performance for French Autoimmune Liver Disease Drug

Genkyotex’s small molecule therapy had encouraging short-term effects on patients with the autoimmune liver disease primary biliary cholangitis in a Phase II trial. Over six weeks, the drug reduced the blood levels of a liver disease biomarker molecule by up to 23% in 92 participants. In patients with late-stage disease, who have few treatments available, […]

November 7, 2018 - 2 minutesmins - By Jonathan Smith

Sitryx immunometabolism cancer inflammation

News and Trends 8 Oct 2018

Oxford Biotech Launches with €26M to Target ‘Immunometabolism’

Sitryx has launched today with the goal of treating cancer and inflammatory conditions by targeting the metabolism of immune cells, a promising area of research. The new company has kicked off with a €26M Series A round co-led by two specialized investors, SV Health and Sofinnova Partners. Sitryx also has investment from GSK, with […]

October 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 19 Sep 2018

Argenx Attracts Huge €250M Investment Following Positive Phase II Trial

Belgian biotech Argenx raised over €250M in public investment on the Nasdaq Stock Market after announcing positive Phase II results for its lead autoimmune drug candidate. The company now plans to progress efgartigimod, an antibody fragment inspired by llama antibodies, to Phase III trials for treatment of the autoimmune blood disease primary immune thrombocytopenia (ITP). […]

September 19, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 23 Jul 2018

Sangamo Acquires French Biotech to Develop CAR-T Therapies for Autoimmune Disease

Sangamo Therapeutics has acquired TxCell with a view to utilizing its CAR-T technology to prevent organ transplant rejections and treat autoimmune disease. Sangamo, based in California, is known for bringing the first in-vivo gene therapy to the market. The company entered into an agreement to purchase TxCell for €72M. Sangamo plans to combine its zinc […]

July 23, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 3 Jul 2018

French Lupus Vaccine Ready to Move Into Phase III

Neovacs, a French biotech, has shown its lupus vaccine can be effective in treating this severe autoimmune disease. Its lupus vaccine works by stimulating the patient’s immune system to produce antibodies against a protein called IFNα that regulates the immune system and is involved in the disease. The study enrolled 185 patients around the globe […]

July 3, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 6 Jun 2018

German DNA Treatment Reduces Ulcerative Colitis Symptoms

Sterna Biologicals has obtained positive Phase IIa data for an ulcerative colitis treatment that uses DNA to inhibit inflammatory proteins, which could add to the diverse approaches being developed to treat inflammatory bowel disease. Sterna Biologicals, based in Marburg, Germany, has clinical data showing its ulcerative colitis treatment reduced the severity of the disease compared […]

June 6, 2018 - 3 minutesmins - By Alexander Burik

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Autoimmune disease

Dutch Antibodies for Autoimmune Diseases Boosted by €15M Series A

Top 10 Biotechs in Lausanne

European Biotechnology in 2019 and Beyond: What’s Hot and What’s Not?

Galapagos Nears First Drug Approval with Phase III Success in Rheumatoid Arthritis

Inflammatory Disease Treatment Backed by €20M Series A

Italian Biotech Raises Big Series A for ‘Gene Therapy 2.0’

Solid Phase II Performance for French Autoimmune Liver Disease Drug

Oxford Biotech Launches with €26M to Target ‘Immunometabolism’

Argenx Attracts Huge €250M Investment Following Positive Phase II Trial

Sangamo Acquires French Biotech to Develop CAR-T Therapies for Autoimmune Disease

French Lupus Vaccine Ready to Move Into Phase III

German DNA Treatment Reduces Ulcerative Colitis Symptoms

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!